Skip to main content
Dx & Vx Co., Ltd. logo

Dx & Vx Co., Ltd. — Investor Relations & Filings

Ticker · 180400 ISIN · KR7180400004 KO Manufacturing
Open in API
Filings indexed 474 across all filing types
Latest filing 2024-11-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 180400

About Dx & Vx Co., Ltd.

https://www.dxvx.com/

Dx & Vx Co., Ltd. is a bio-healthcare company specializing in diagnostics and vaccine development. Its diagnostics division offers molecular diagnostic solutions, genomics and bioinformatics services, and customized companion diagnostics (CDx), leveraging an AI-based genome analysis platform. The company's therapeutic pipeline is centered on an innovative mRNA vaccine platform designed for long-term storage at room temperature. Key development areas include vaccines for infectious diseases, immuno-therapeutic cancer vaccines, oral treatments for obesity, and therapies for eye conditions. Additionally, Dx & Vx provides contract development, manufacturing, and sales organization (CDMO/CSO) services and commercializes microbiome-based products and health supplements.

Recent filings

Filing Released Lang Actions
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company '디엑스앤브이엑스' (Dx&Vx Co., Ltd.) covering the period from January 1, 2024, to September 30, 2024. It contains detailed corporate information, business descriptions, capital structure, and governance details, which are characteristic of a comprehensive interim financial report. It is not a mere announcement or certification, as it provides substantive business and financial data. 9M 2024
2024-11-14 Korean
[기재정정]주요사항보고서(회사합병결정)
M&A Activity Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a corporate merger (회사합병 결정) between DX&VX Co., Ltd. and Evixgen Co., Ltd. It details the merger schedule, rationale, financial impact, and valuation ratios. This type of filing is specifically related to M&A activity and corporate restructuring. In the context of the provided categories, 'TAR' (M&A Activity) is the most accurate classification for documents detailing merger proposals, takeover bids, and absorption agreements.
2024-11-11 Korean
[기재정정]주요사항보고서(회사합병결정)
M&A Activity Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a corporate merger (회사합병 결정) between DX&VX Co., Ltd. and Avixgen Co., Ltd. It details the merger ratio, rationale, financial impact, and schedule. While it mentions a future securities registration statement, this document itself is the formal regulatory filing announcing the merger decision to the Korea Exchange. Under the provided categories, M&A activity (mergers and acquisitions) is classified as 'TAR'.
2024-11-11 Korean
주주총회소집결의 (임시주주총회)
AGM Information Classification · 98% confidence The document is a formal notice of an Extraordinary General Meeting (EGM) for DXVX, detailing the date, location, and agenda items (such as the appointment of a director). This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming votes, which falls under the Proxy Solicitation & Information Statement category.
2024-11-05 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for an upcoming Extraordinary General Meeting (EGM). It does not contain the full proxy materials or the meeting results, but rather serves as a formal notice of the record date for shareholder eligibility. Given it is a regulatory announcement regarding corporate governance procedures that does not fit into specific categories like 'DVA' (results) or 'PSI' (proxy solicitation materials), it is best classified as a general regulatory filing.
2024-11-05 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. This specific document details a change in shareholding (specifically the sale of convertible bonds) by a major shareholder (Moorim Capital and its special related party). In the provided filing categories, this corresponds to a 'Major Shareholding Notification' (MRQ).
2024-10-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.